1. Sarma AV, Wei JT. Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms. N Engl J Med. 2012; 367:248–257.
2. Lee YJ, Lee JW, Park J, Seo SI, Chung JI, Yoo TK, et al. Nationwide incidence and treatment pattern of benign prostatic hyperplasia in Korea. Investig Clin Urol. 2016; 57:424–430.
![crossref](/image/icon/bnr_ref_cross.gif)
3. Gratzke C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C, et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2015; 67:1099–1109.
![crossref](/image/icon/bnr_ref_cross.gif)
4. Barkin J, Diles D, Franks B, Berner T. Alpha blocker monotherapy versus combination therapy with antimuscarinics in men with persistent LUTS refractory to alpha-adrenergic treatment: patterns of persistence. Can J Urol. 2015; 22:7914–7923.
5. Cho SY, Ro YK, Kim H, Son H. Preoperative urinary retention increased the risk of urinary retention after photoselective vaporization of the prostate. World J Mens Health. 2015; 33:182–187.
![crossref](/image/icon/bnr_ref_cross.gif)
6. Shin YS, Zhang LT, You JH, Choi IS, Zhao C, Park JK. Efficacy and safety of tamsulosin hydrochloride 0.2 mg and combination of tamsulosin hydrochloride 0.2 mg plus solifenacin succinate 5 mg after transurethral resection of the prostate: a prospective, randomized controlled trial. Clin Interv Aging. 2016; 11:1301–1307.
7. Pagano E, Laudato M, Griffo M, Capasso R. Phytotherapy of benign prostatic hyperplasia. A minireview. Phytother Res. 2014; 28:949–955.
![crossref](/image/icon/bnr_ref_cross.gif)
8. Park JW, Jeong HC, Moon HW, Cho SJ, Yang JH, Kim WH, et al. Anti-inflammatory and antimicrobial effects of a novel herbal formulation (WSY-1075) in a chronic bacterial prostatitis rat model. World J Mens Health. 2016; 34:179–185.
![crossref](/image/icon/bnr_ref_cross.gif)
9. Jin LH, Andersson KE, Han JU, Kwon YH, Park CS, Shin HY, et al. Persistent detrusor overactivity in rats after relief of partial urethral obstruction. Am J Physiol Regul Integr Comp Physiol. 2011; 301:R896–R904.
![crossref](/image/icon/bnr_ref_cross.gif)
10. Nishiguchi J, Kwon DD, Kaiho Y, Chancellor MB, Kumon H, Snyder PB, et al. Suppression of detrusor overactivity in rats with bladder outlet obstruction by a type 4 phosphodiesterase inhibitor. BJU Int. 2007; 99:680–686.
![crossref](/image/icon/bnr_ref_cross.gif)
11. Lin AT, Juan YS. Ischemia, hypoxia and oxidative stress in bladder outlet obstruction and bladder overdistention injury. Low Urin Tract Symptoms. 2012; 4:Suppl 1. 27–31.
![crossref](/image/icon/bnr_ref_cross.gif)
12. Koritsiadis G, Stravodimos K, Koutalellis G, Agrogiannis G, Koritsiadis S, Lazaris A, et al. Immunohistochemical estimation of hypoxia in human obstructed bladder and correlation with clinical variables. BJU Int. 2008; 102:328–332.
![crossref](/image/icon/bnr_ref_cross.gif)
13. Azadzoi KM, Tarcan T, Kozlowski R, Krane RJ, Siroky MB. Overactivity and structural changes in the chronically ischemic bladder. J Urol. 1999; 162:1768–1778.
![crossref](/image/icon/bnr_ref_cross.gif)
14. Parsons BA, Drake MJ. Animal models in overactive bladder research. Handb Exp Pharmacol. 2011; (202):15–43.
![crossref](/image/icon/bnr_ref_cross.gif)
15. Sasaki M, Joh T. Oxidative stress and ischemia-reperfusion injury in gastrointestinal tract and antioxidant, protective agents. J Clin Biochem Nutr. 2007; 40:1–12.
![crossref](/image/icon/bnr_ref_cross.gif)
16. Matsui T, Oka M, Fukui T, Tanaka M, Oyama T, Sagawa K, et al. Suppression of bladder overactivity and oxidative stress by the phytotherapeutic agent, Eviprostat, in a rat model of atherosclerosis-induced chronic bladder ischemia. Int J Urol. 2012; 19:669–675.
![crossref](/image/icon/bnr_ref_cross.gif)
17. Nomiya M, Andersson KE, Yamaguchi O. Chronic bladder ischemia and oxidative stress: new pharmacotherapeutic targets for lower urinary tract symptoms. Int J Urol. 2015; 22:40–46.
![crossref](/image/icon/bnr_ref_cross.gif)
18. Juan YS, Chuang SM, Mannikarottu A, Huang CH, Li S, Schuler C, et al. Coenzyme Q10 diminishes ischemia-reperfusion induced apoptosis and nerve injury in rabbit urinary bladder. Neurourol Urodyn. 2009; 28:339–342.
![crossref](/image/icon/bnr_ref_cross.gif)
19. Kim JW, Jang HA, Bae JH, Lee JG. Effects of coenzyme Q10 on bladder dysfunction induced by chronic bladder ischemia in a rat model. J Urol. 2013; 189:2371–2376.
![crossref](/image/icon/bnr_ref_cross.gif)
20. Kawai Y, Oka M, Kyotani J, Oyama T, Matsumoto S, Kakizaki H. Effect of the phytotherapeutic agent eviprostat on the bladder in a rat model of bladder overdistension/emptying. Neurourol Urodyn. 2013; 32:1031–1037.
![crossref](/image/icon/bnr_ref_cross.gif)
21. Oka M, Fukui T, Ueda M, Tagaya M, Oyama T, Tanaka M. Suppression of bladder oxidative stress and inflammation by a phytotherapeutic agent in a rat model of partial bladder outlet obstruction. J Urol. 2009; 182:382–390.
![crossref](/image/icon/bnr_ref_cross.gif)
22. Parekh MH, Lobel R, O'Connor LJ, Leggett RE, Levin RM. Protective effect of vitamin E on the response of the rabbit bladder to partial outlet obstruction. J Urol. 2001; 166:341–346.
![crossref](/image/icon/bnr_ref_cross.gif)
23. Ishigooka M, Hashimoto T, Hayami S, Tomaru M, Nakada T, Mitobe K. Clinical and retrospective evaluation of Eviprostat: a non-hormonal and non-neuropharmacological agent for benign prostatic hyperplasia. Int Urol Nephrol. 1995; 27:61–66.
![crossref](/image/icon/bnr_ref_cross.gif)
24. Sugimoto M, Oka M, Tsunemori H, Yamashita M, Kakehi Y. Effect of a phytotherapeutic agent, Eviprostat®, on prostatic and urinary cytokines/chemokines in a rat model of nonbacterial prostatitis. Prostate. 2011; 71:438–444.
![crossref](/image/icon/bnr_ref_cross.gif)
25. Che CT, Wang ZJ, Chow MS, Lam CW. Herb-herb combination for therapeutic enhancement and advancement: theory, practice and future perspectives. Molecules. 2013; 18:5125–5141.
![crossref](/image/icon/bnr_ref_cross.gif)
26. Kim HJ, Kim BH, Kim YC. Antioxidative action of corni fructus aqueous extract on kidneys of diabetic mice. Toxicol Res. 2011; 27:37–41.
![crossref](/image/icon/bnr_ref_cross.gif)
27. Park WH, Hong MY, Chung KH, Kim HM, Lee YC, Kim CH. Effects of traditional herbal medicine, Hwaotang, on atherosclerosis using the spontaneous familial hypercholesterolemia model, Kurosawa and Kusanagi-hypercholesterolemic rabbits and the venous thrombosis rats. Phytother Res. 2005; 19:846–853.
![crossref](/image/icon/bnr_ref_cross.gif)
28. Lam P, Cheung F, Tan HY, Wang N, Yuen MF, Feng Y. Hepatoprotective effects of Chinese medicinal herbs: a focus on anti-inflammatory and anti-oxidative activities. Int J Mol Sci. 2016; 17:465.
![crossref](/image/icon/bnr_ref_cross.gif)
29. Hegde SS. Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol. 2006; 147:Suppl 2. S80–S87.
![crossref](/image/icon/bnr_ref_cross.gif)